BofA Remains Bullish on McKesson (MCK) Following Strong Third Quarter Performance

McKesson Corporation (NYSE:MCK) is one of the best performing S&P 500 stocks in the last five years.

BofA Remains Bullish on McKesson (MCK) Following Strong Third Quarter Performance

On February 5, 2026, BofA reaffirmed its ‘Buy’ rating on McKesson Corporation (NYSE:MCK) and increased its price target from $950 to $970. Describing the third quarter as strong, the firm pointed to revenue and EPS, both of which exceeded street expectations. Citing the North American Pharmaceutical segment’s solid performance and the Oncology & Multispecialty segment’s ongoing strength, BofA raised its FY26 and FY27 EPS projections.

The analyst update followed McKesson Corporation (NYSE:MCK)’s February 4, 2026, Q3 earnings and outlook update, in which the company raised its fiscal 2026 adjusted EPS forecast from a prior range of $38.35-$38.85 to $38.80-$39.20.

Additionally, McKesson Corporation (NYSE:MCK) reported third-quarter revenue of $106.16 billion, exceeding the $105.86 billion forecast, and adjusted EPS of $9.34, above the $9.22 forecast. The demand for specialty drugs and strong prescription volumes helped the U.S. pharmaceutical segment’s sales to rise 9% to $88.30 billion.

McKesson Corporation (NYSE:MCK), a healthcare services company, offers pharmaceutical distribution, specialty drug solutions, prescription technology services, and medical-surgical supplies across the United States and international markets.

While we acknowledge the potential of MCK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MCK and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: What Are the Best Stocks to Buy Right Now? and 10 Stocks Under $1 That Will Explode.

Disclosure: None.